Lipoatrophy is a thing of the past, or is it?

Diabetic Medicine

Volumn 24, Issue 12, 2007, Pages 1470-1472

  Hussein, S F ^a   Siddique, H ^a   Coates, P ^a   Green, J ^a  

^a Stafford District Hospital Diabetes and Endocrine   (United Kingdom)

Author keywords

Biphasic insulin Aspart; Insulin analogues; Lipoatrophy; Novomix 30; Recombinant human insulin

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART;

AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIPOATROPHY; POLYDIPSIA; POLYURIA; URINALYSIS; WEIGHT REDUCTION;

AGED; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; LIPODYSTROPHY;

EID: 36549011695     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02300.x     Document Type: Article

References (3)

1. Mu L, Goldman JM. Human recombinant DNA insulin-induced lipoatrophy in patient with type 2 diabetes mellitus. Endocr Pract 2000 6 : 151 152.
2. Reeves WG, Tattersall RB. Insulin induced lipoatrophy: evidence for an immune pathogenesis. Br Med J 1980 280 : 1500 1503.
3. Atlan-Gepner C, Bondgrand P, Farnarier C, Xerri L, Choux R, Gauthier JF et al. Insulin-induced lipoatrophy in type 4 (4)diabetes: a possible tumor necrosis factor-α-mediated dedifferentiation of adipocytes. Diabetes Care 1996 19 : 1283 1285.